18F-Labeled 4-Anilidopiperidines
Journal of Medicinal Chemistry, 2005, Vol. 48, No. 24 7731
1
-substituted 4-(propananilido) perhydroazepines as ring- ex-
activation studies of the cloned mouse δ-, µ, and κ-opioid
receptors. Protein Eng. 1999, 12, 927-942. (d) Zhang, Y.; Sham,
Y. Y.; Rajamani, R.; Gao, J.; Portoghese, P. S. Homology
modeling and molecular dynamics simulation of the mu opioid
receptor in a membrane-aqueous system. Chem. Bio Chem. 2005,
panded analogues. J. Med. Chem. 1980, 23, 895-899. (c) Borne,
R. F.; Law, S.-Y.; Kapeghian, J. C.; Masten, L. W. Evaluation of
2
-azabicyclo[2.2.2] octane analogues of 4-anilidopiperidine an-
algesics. J. Pharm. Sci. 1980, 69, 1104-1106. (d) Fernandez,
M. J.; Huertas, R. M.; Galvez, E.; Orjales, A.; Berisa, A.; Labeaga,
L.; Gago, F.; Fonseca, I.; Sanz- Aparicio, J.; Cano, F. H.; Albert,
A.; Fayor, J. Synthesis, and structural, conformational and
pharmacolgical studies of new fentanyl derivatives of the nor-
granatane System. J. Chem. Soc., Perkin Trans. 2 1992, 687-
6
, 853-859.
(
28) Bissantz, C.; Bernard, P.; Hibert, M.; Rognan, D. Protein-based
virtual screening of chemical databases. II. Are homology models
of G-protein coupled receptors suitable targets? Proteins Struct.
Funct. Genet. 2003, 50, 5-25.
29) (a) Okada, T.; Ernst, O. P.; Palczewski, K.; Hofmann, K. P.
Activation of rhodopsin: new insights from structural and
biochemical studies. Trends Biochem. Sci. 2001, 26, 318-324.
695. (e) Van Daele, P. G.; De Bruyn, M. F.; Boey, J. M.; Sanczuk,
(
S.; Agten, J. T.; Janssen, P. A. Synthetic analgesics: N-(1-[2-
arylethyl]-4-substituted 4-piperidinyl N-arylalkanamides. Arz-
neim.-Forsch. Drug Res. 1976, 26, 1521-1531.
(
b) Hubbell, W. L.; Altenbach, C.; Hubbell, C. M.; Khorana, H.
(
13) (a) Colapet, J. A.; Diamantidis, G.; Spencer, H. K.; Spaulding,
T. C.; Rudo, F. G. Synthesis and pharmacological evaluation of
G. Rhodopsin structure, dynamics, and activation: a perspective
from crystallography, site-directed spin labeling, sulfhydryl
reactivity, and disulfide cross-linking. Adv. Protein Chem. 2003,
63, 243-290.
4
,4-disubstituted piperidines. J. Med. Chem. 1989, 32, 968-974.
(
b) France, C. P.; Winger, G.; Madzihradsky, F.; Seggel, M. G.;
Rice, K. C.; Woods, J. H. Mirfentanil: Pharmacological profile
of a novel fentanyl derivative with opioid and nonopioid effects.
J. Pharmacol. Exp. Ther. 1991, 258, 502-510. (c) France, C. P.;
Gerak, L. R.; Flynn, D.; Winger, G. D.; Medzihradsky, F.; Bagley,
J. R.; Brockunier, L. L.; Woods, J. H. Behavioral effects and
receptor binding affinities of fentanyl derivatives in rhesus
monkeys. J. Pharmacol. Exp. Ther. 1995, 274, 17-28. (d)
Cometta-Morini, C.; Maguire, P. A.; Loew, G. H. Molecular
determinants of µ-receptor recognition for the fentanyl class of
compounds. Mol. Pharmacol. 1992, 41, 185-196.
(30) (a) Peeters, O. M.; Blaton, N. M.; De Ranter, C. J.; van Herk, A.
M.; Goubitz, K.; Crystal and Molecular Structure of N-[1-(2-
phenylethyl)-4-piperidinylium]-N-phenylpropanamide (fentanyl)
citrate-toluene Solvate. J. Cryst. Mol. Struct. 1979, 9, 153-161.
(
b) Flippen-Anderson, J. L.; George, C.; Bertha, C. M.; Rice, K.
C. X-ray crystal structures of potent opioid receptor ligands:
Etonitazene, cis-(+)-3-Methylfentanyl, Etorphine, Diprenor-
phine, and Buprenorphine. Heterocycles 1994, 39, 751-766. (c)
Brine, G. A.; Stark, P. A.; Liu, Y.; Carroll, F. I.; Singh, P.; Xu,
H.; Rothman, R. B. Enantiomers of diastereomeric cis-N-[1-(2-
hydroxy-2-phenylethyl)-3-methyl-4-piperidyl]-N-phenylpropana-
mides: Synthesis, X-ray analysis, and biological activities. J.
Med. Chem. 1995, 38, 1547-1557.
(
(
14) (a) Janssen, P. A. J.; Van Daele, G. H. P. N-(4-piperidinyl)-N-
phenylamides and -carbamates. US patent 3,998,834, 1976. (b)
Janssen, P. A. J.; Van Daele, G. H. P. N-(4-piperidinyl)-N-
phenylamides. US patent 4,179,569, 1979.
15) Fowler, C. B.; Pogozheva, I. D.; Lomize, A. L.; LeVine, H. 3rd;
Mosberg, H. I. Complex of an active mu-opioid receptor with a
cyclic peptide agonist modeled from experimental constraints.
Biochemistry. 2004, 43, 15796-15810. The model of the µ-recep-
tor is available from the following web site: http://mosberglab-
(31) Brine, G. A.; Boldt, K. G.; Huang, P.-T.; Sawyer, D. K.; Carroll,
F. I. Carbon-13 nuclear magnetic resonance spectra of fentanyl
analogues. J. Heterocycl. Chem. 1989, 26, 677-686.
(32) (a) Martins, J.; Andrews, P. Conformation-activity relationships
of opiate analgesics. J. Comput.-Aided Mol. Des. 1987, 1, 53-
.
phar.umich.edu/resources/index.php.
(
(
16) Jewett, D. M.; Kilbourn, M. R. In vivo evaluation of new
carfentanil-based radioligands for the mu opiate receptor. Nucl.
Med. Biol. 2004, 31, 321-325.
7
2. (b) Subramanian, G.; Ferguson, D. M. Conformational
landscape of selective mu-opioid agonists in gas phase and in
aqueous solution: the fentanyl series. Drug Des. Discovery 2000,
1
17) Saji, H.; Tsutsumi, D.; Magata, Y.; Iida, Y.; Konishi, J.; Yokoya-
7, 55-67.
1
1
ma, A. Preparation and biodistribution in mice of [ C]carfen-
tanil: a radiopharmaceutical for studying brain µ-opioid recep-
tors by positron emission tomography. Ann. Nucl. Med. 1992,
(
33) The numbering of the human µ receptor corresponds to that of
the the rat µ receptor for consistency with mutagenesis data and
to allow an easy comparison with the previously reported
6
, 63-67.
2
7
µ-receptor models.
(
18) Wester, H.-J.; Willoch, F.; T o¨ lle, T. R.; Munz, F.; Herz, M.; Øye,
1
8
(34) (a) Surratt, C. K.; Johnson, P. S.; Moriwaki, A.; Seidleck, B. K.;
Blaschak, C. J.; Wang, J. B.; Uhl, G. R.m-Opiate receptor:
Charged transmembrane domain amino acids are critical for
agonist recognition and intrinsic activity. Biol. Chem. 1994, 269,
20548-20553. (b) Mansour A.; Taylor L. P.; Fine J. L.; Thompson
R. C.; Hoversten M. T.; Mosberg H. I.; Watson S. J.; Akil H. Key
residues defining the mu-opioid receptor binding pocket: a site-
directed mutagenesis study. J. Neurochem. 1997, 68, 344-353.
(c) Li, J. G.; Chen, C.; Yin J.; Rice, K.; Zhang, Y.; Matecka, D.;
de Riel, J. K.; DesJarlais, R. L.; Liu-Chen, L. Y. ASP147 in the
third transmembrane helix of the rat mu opioid receptor forms
ion-pairing with morphine and naltrexone. Life Sci. 1999, 65,
I.; Schadrack, J.; Schwaiger, M.; Bartenstein, P. 6-O-(2-[ F]-
18
fluoroethyl)6-O-desmethyl-diprenorphine ([ F]DPN): Synthesis,
11
biological evaluation, and comparison with [ C]DPN in humans.
J. Nucl. Med. 2000, 41, 1279-1286.
(
19) Endres, C. J.; Bencherif, B.; Hilton, J.; Madar, I.; Frost, J. J.
Quantification of brain mu-opioid receptors with [11C]carfentanil:
reference-tissue methods. Nucl. Med. Biol. 2003, 30, 177-186.
20) Halldin, C.; Swahn, C. G.; Farde, L.; Sedvall, G. Radioligand
disposition and metabolism-Key information in drug develop-
ment. In PET for Drug Development and Evaluation; Comar,
D., Ed.; Kluwer Academic Publishers: Boston, 1995; pp 55-61.
21) Carson, R. E.; Lang, L.; Watabe, H.; Der, M. G.; Adams, H. R.;
Jagoda, E.; Herscovitch, P.; Eckelman, W. C. PET evaluation of
(
(
1
75-85. (d) Chen, C.; Yin, J.; Riel, J. K.; DesJarlais, R. L.;
1
8
[
F]FCWAY, an analog of the 5-HT1A receptor antagonist,
Raveglia L. F.; Zhu, J.; Liu-Chen, L. Y.; Determination of the
WAY-100635. Nucl. Med. Biol. 2000, 27, 493-497.
3
amino acid residue involved in [ H]beta-funaltrexamine covalent
(
22) Ma, Y.; Kiesewetter, D. O.; Lang, L.; Der, M.; Huang, B.; Carson,
R. E.; Eckelman, W. C. Determination of [18F]FCWAY, [18F]FP-
binding in the cloned rat mu-opioid receptor. J Biol. Chem. 1996,
2
71, 21422-21429.
TZTP, and their metabolites in plasma using rapid and efficient
(
35) Pogozheva, I. D.; Lomize, A. L.; Mosberg, H. I. Opioid Receptor
Three-dimensional Structures from Distance Geometry Calcula-
tions with Hydrogen Bonding Constraints. Biophys. J. 1998, 75,
612-634.
(36) Tang, Y.; Chen, K. X.; Jiang, H. L.; Wang, Z. X.; Ji, R. Y.; Chi,
Z. Q. Molecular Modeling of the µ-Opioid Receptor and its
Interaction with OHMefentanyl. Acta Pharmacol. Sin. 1996, 17,
156-160.
liquid-liquid and solid-phase extractions. Nucl. Med. Biol. 2003,
3
0, 233-240.
(
(
(
(
23) Ravert, H. T.; Bencherif, B.; Madar, I.; Frost J. J. PET imaging
of opioid receptors in pain: progress and new directions. Curr.
Pharm. Des. 2004, 10, 759-768.
24) Brodsky, M.; Elliott, K.; Hynansky, A.; Jenab, S.; Inturrisi, C.
E. Quantitation of mu-opioid receptor (MOR-1) mRNA in
selected regions of the rat CNS. Neuroreport 1995, 6, 725-729.
25) Raynor, K.; Kong, H.; Chen, Y.; Yasuda, K.; Yu, L.; Bell, G. I.;
Reisine, T. Pharmacological characterization of the cloned κ-,
δ-, and µ-opioid receptors. Mol. Pharm. 1994, 45, 330-334.
26) Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Mo-
toshima, H.; Fox, B. A.; Trong, I L.; Teller, D. C.; Okada, T.;
Stenkamp, R. E.; Yamamoto, M.; Miyano, M. Crystal structure
of Rhodopsin: a G protein-coupled receptor. Science 2000, 289,
(
37) Xu, H.; Lu, Y.-F.; Partilla, J. S.; Zheng, Q.-X.; Wang, J.-B.; Brine,
G. A.; Carroll, I.; Rice, K. C.; Chen, K.-X.; Chi, Z.-Q.; Rothman,
R. B. Opioid Peptide Receptor Studies, 11: Involvement of
Tyr148, Trp318, and His319 of the Rat µ-Opioid Receptor in
Binding of µ-Selective Ligands. Synapse 1999, 32, 23-28.
38) Ulens, C.; Van Boven, M.; Daenens, P.; Tytgat, J.; Interaction
of p-fluorofentanyl on cloned human opioid receptors and
exploration of the role of Trp-318 and His-319 in mu-opioid
receptor selectivity. J. Pharmacol. Exp. Ther. 2000, 294, 1024-
(
7
39-745.
(
27) (a) Strahs, D.; Weinstein, H. Comparative modeling and molec-
ular dynamics studies of the δ, κ, and µ-opioid receptors. Protein
Eng. 1997, 10, 1019-1038. (b) Pogozheva, I. D.; Lomize, A. L.;
Mosberg, H. I. Opioid receptor three-dimensional structures from
distance geometry calculations with hydrogen bonding con-
straints. Biophys. J. 1998, 75, 612-634. (c) Filizola, M.;
Laakkonen, L.; Loew, G. H. 3D modeling, ligand binding, and
1
033.
(39) Shi, L.; Liapakis, G.; Xu, R.; Guarnieri, F.; Ballesteros, J. A.;
Javitch, J. A. R-2-adrenergic receptor activation. Modulation of
the proline kink in transmembrane 6 by a rotamer toggle switch.
J. Biol. Chem. 2002, 277, 40989-40996.